

# 1 Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated 2 convalescent plasma sources.

3

4 David J Sullivan<sup>1</sup> Massimo Franchini<sup>2</sup>, Michael J. Joyner<sup>3</sup>, Arturo Casadevall<sup>1</sup>, Daniele Focosi<sup>4,#</sup>,

5

6 <sup>1</sup>Johns Hopkins Bloomberg School of Public Health and School of Medicine, Baltimore, MD 21218, USA;  
7 [dsullivan7@jhmi.edu](mailto:dsullivan7@jhmi.edu), [acasade1@jhu.edu](mailto:acasade1@jhu.edu),

8 <sup>2</sup>Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy; [massimo.franchini@asst-](mailto:massimo.franchini@asst-mantova.it)  
9 [mantova.it](mailto:massimo.franchini@asst-mantova.it)

10 <sup>3</sup>Department of Anesthesiology & Perioperative Medicine, Mayo Clinic, Rochester, MN 55902, USA  
11 [joyner.michael@mayo.edu](mailto:joyner.michael@mayo.edu) ;

12 <sup>4</sup>North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.

13

14 <sup>#</sup>corresponding author: via Paradisa 2, 56124 Pisa, Italy. E-mail: [daniele.focosi@gmail.com](mailto:daniele.focosi@gmail.com) .

15 **Keywords:** COVID19; Omicron; convalescent plasma; vaccine; neutralizing antibodies.

16 **Word count:** abstract 220; body 2979.

17 **Acknowledgements:** none.

18 **Funding Information:** The analysis was supported by the U.S. Department of Defense's Joint Program  
19 Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in  
20 collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012) (D.S), with  
21 additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health  
22 (NIH) National Institute of Allergy and Infectious Diseases (NIAID) 3R01AI152078-01S1) (A.C).

23 **Author contributions:** D.F. and M.J.J. conceived the manuscript; D.F., D.J.S. and M.F. analyzed the  
24 literature, curated tables and wrote manuscripts; M.F. provided Figure 1; D.J.S. provided Figures 2 -5.A.C.  
25 and M.J.J. revised the manuscript.

26 **Data availability statement:** The datasets generated during and/or analysed during the current study are  
27 available from the corresponding author on reasonable request

## 28 Abstract

29 The latest SARS-CoV-2 variant of concern Omicron, with its immune escape from therapeutic anti-Spike  
30 monoclonal antibodies and WA-1 vaccine-elicited sera, demonstrates the continued relevance of COVID-  
31 19 convalescent plasma (CCP) therapies. Lessons learnt from previous usage of CCP suggests focusing on  
32 early outpatients and immunocompromised recipients, with high neutralizing antibody (nAb) titer units.  
33 In this analysis we systematically reviewed Omicron-neutralizing plasma activity data, and found that  
34 approximately 47% (424/902) of CCP from unvaccinated pre-Omicron donors neutralizes Omicron BA.1  
35 with a very low geomean of geometric mean titers for 50% neutralization  $GM(GMT_{50})$  of about 13,  
36 representing a more than 20-fold reduction from WA-1 neutralization. Two doses of mRNA vaccines in  
37 nonconvalescent subjects had a similar 50% percent neutralization with Omicron BA.1 neutralization  
38  $GM(GMT_{50})$  of about 27. However, plasma from vaccinees recovered from either previous pre-Omicron  
39 variants of concern infection, Omicron BA.1 infection, or third-dose uninfected vaccinees was nearly  
40 100% neutralizing against Omicron BA.1, BA.2 and BA.4/5 with  $GM(GMT_{50})$  all over 189, 10 times higher  
41 than pre-Omicron CCP. Fully vaccinated and post-BA.1 plasma (Vax-CCP) had  $GM(GMT_{50})$  over 450 for  
42 BA.4/5 and over 1500 for BA.1 and BA.2. These findings have implications for both CCP stocks collected in  
43 prior pandemic periods and plans to restart CCP collections. Thus, Vax-CCP provides an effective tool to  
44 combat ongoing variants that defeat therapeutic monoclonal antibodies.

## Introduction

The SARS-CoV-2 Omicron variant of concern (VOC) (originally named VUI-21NOV-01 by Public Health England and belonging to GISAID clade GRA(B.1.1.529+BA.\*) was first reported on November 8, 2021 in South Africa, and shortly thereafter was also detected all around the world. Omicron mutations impact 27% of T cell epitopes<sup>1</sup> and 31% of B cell epitopes of the Spike protein, while percentages for other VOC were much lower<sup>2</sup>. The Omicron variant has further evolved to several sublineages which are named by PANGO phylogeny using the BA alias: the BA.1 wave of Winter 2021-2022 has been suddenly replaced by BA.2 and BA.2.12.1 in Spring 2022, and by the BA.4 and BA.5 waves in Summer 2022.

The VOC Omicron is reducing the efficacy of all vaccines approved to date (unless 3 doses are delivered) and is initiating an unexpected boost in COVID19 convalescent plasma (CCP) usage, with Omicron being treated as a shifted novel virus instead of a SARS-CoV-2 variant drift. Two years into the pandemics, we are back to the starting line for some therapeutic classes. Specifically, Omicron escapes viral neutralization by most monoclonal antibodies (mAbs) authorized to date with the lone exception of bebtelovimab<sup>3</sup>. Despite the development of promising oral small-molecule antivirals (molnupiravir and nirmatrelvir), the logistical and economical hurdles for deploying these drugs worldwide has prevented their immediate and widespread availability, and concerns remain regarding both molnupiravir (both safety<sup>4</sup> and efficacy<sup>5</sup>) and nirmatrelvir (efficacy), especially in immunocompromised subjects. CCP was used as a frontline treatment from the very beginning of the pandemic. Efficacy outcomes have been mixed to date, with most failures explained by low dose, late usage, or both, but efficacy of high-titer CCP has been definitively proven in outpatients with mild disease stages<sup>6, 7</sup>. Neutralizing antibody (nAb) efficacy against VOC remains a prerequisite to support CCP usage, which can now be collected from vaccinated convalescents, including donors recovered from breakthrough infections (so-called “hybrid plasma” or “Vax-CCP”)<sup>8</sup>: pre-Omicron evidence suggest that those nAbs have higher titers and are more effective against VOCs than those from unvaccinated convalescents<sup>9, 10</sup>. From a regulatory viewpoint, to date, plasma from vaccinees that have never been convalescent does not fall within the FDA emergency use authorization

There are tens of different vaccine schedules theoretically possible according to EMA and FDA approvals, including a number of homologous or heterologous boosts, but the most commonly delivered schedules in the western hemisphere have been: 1) BNT162b2 or mRNA-1273 for 2 doses eventually followed by a homologous boost; 2) ChAdOx1 for 2 doses eventually followed by a BNT162b2 boost; and 3) Ad26.COV2.S for 1 dose eventually followed by a BNT162b2 boost<sup>11</sup>. Many more inactivated vaccines have been in use in low-and-middle income countries (LMIC), which are target regions for CCP therapy: this is feasible given the lower number of patients at risk for disease progression there (lower incidences of obesity, diabetes, and hypertension, and lower median age) and the already widespread occurrence of collection and transfusion facilities. Most blood donors there have already received the vaccine schedule before, after or without having been infected, with a nAb titer generally declining over months<sup>12</sup>. Hence identifying the settings where the nAb titer is highest will definitively increase the efficacy of CCP collections. Variations in nAb titers against a given SARS-CoV-2 strain are usually reported as fold-changes in geometric mean titer of antibodies neutralizing 50% of cytopathic effect (GMT<sub>50</sub>) compared to wild-type strains: nevertheless, fold-changes for groups that include non-responders can lead to highly artificial results and possibly over-interpretation. Rigorous studies have hence reported the percentage of

responders as primary outcome and provided fold-changes of GMT<sub>50</sub> where calculation is reasonable (100% responders in both arms)<sup>13</sup>.

To date the most rigorous data repository for SARS-CoV-2 sensitivity to antivirals is the Stanford University Coronavirus Antiviral & Resistance Database, but as of July 24, 2022 the tables there summarizing “Convalescent plasma” and “Vaccinee plasma” (<https://covdb.stanford.edu/search-drdb>) do not dissect the different heterologous or homologous vaccination schemes, the simultaneous occurrence of vaccination and convalescence, or the time from infection/vaccine to neutralization assay. Consequently, a more in-depth analysis is needed to better stratify CCP types.

## Methods

On August 11, 2022, we searched PubMed, medRxiv and bioRxiv for research investigating the efficacy of CCP (either from vaccinated or unvaccinated donors) against SARS-CoV-2 VOC Omicron (pre)published after December 1, 2019, using English language as the only restriction. In PubMed we used the search query “(“convalescent plasma” or “convalescent serum”) AND (“neutralization” or “neutralizing”) AND “SARS-CoV-2””, while in bioRxiv and medRxiv we searched for abstract or title containing “convalescent, SARS-CoV-2, neutralization” (match all words). When a preprint was published, the latter was used for analysis. We also screened the reference lists of reviewed articles for additional studies not captured in our initial literature search. Articles underwent evaluation for inclusion by two assessors (D.F. and D.J.S.) and disagreements were resolved by a third senior assessor (A.C.). We excluded review articles, meta-analyses, studies reporting antibody levels by serological assays other than neutralization, as well as studies exclusively analyzing nAbs in vaccine-elicited plasma/serum from non-convalescent subjects. In unvaccinated subjects, convalescence was annotated according to infecting sublineage (pre-VOC Alpha, VOC Alpha, VOC Beta, VOC Delta, or VOC Omicron BA.1 sublineages). Given the heterologous immunity that develops after vaccination in convalescents, the infecting lineage was not annotated in vaccine recipients. In vaccinees, strata were created for 2 homologous doses, 3 homologous doses, or post-COVID-19 and post-vaccination (Vax-CCP). The type of viral assay (live or pseudovirus), time interval to blood sample, geometric mean, minimum and maximum neutralizing 50% dilutional titer for WA-1 (pre-Alpha wild-type) and Omicron sublineages BA.1, BA.2 and BA.4/5, and number out of total that neutralized Omicron was abstracted from study text, graphs and tables.

Statistical significance between log<sub>10</sub> transformed geometric study means was investigated using Tukey’s test.

## Results

Our literature search identified 31 studies dealing with the original Omicron lineage (BA.1), that were then manually mined for relevant details: the PRISMA flowchart for study selection is provided in Figure 1. Given the urgency to assess efficacy against the upcoming VOC Omicron, many studies (with a few exceptions<sup>14, 15, 16, 17</sup>) relied on Omicron BA.1 pseudovirus neutralization assays, which, as opposed to live authentic virus neutralization assays, are scalable, do not require BSL-3 facilities, and provide results in

less than 1 week. Plasma dilutions were expressed in the studies as GMT<sub>50</sub> of nAb, and fold-reduction in GMT<sub>50</sub> compared to wild-type SARS-CoV-2 (e.g., WA-1) was the most common way of reporting changes, which reduces variability due to differences in the neutralization assays used. In comparing the large number of diverse studies with more than 100-fold plasma dilutional titers, we took the geometric mean of the individual study GMT<sub>50</sub>, deriving a geomean of GMT<sub>50</sub> (GM(GMT<sub>50</sub>)).

Figure 2 and Table 1 summarize that neutralizing activity to WA-1 from CCP collected from subjects infected with pre-Alpha SARS-CoV-2 (Supplementary Table 1), Alpha VOC (Supplementary Table 2), Beta VOC (Supplementary Table 3), Delta VOC (Supplementary Table 4) or plasma from nonconvalescent subjects vaccinated with 2 mRNA vaccine doses (Supplementary Tables 5 and 6). The same plasma types computed a geometric mean of multiple GMT<sub>50</sub> from many studies with about a 20-fold reduction against BA.1 geomeans compared to wild-type SARS-CoV-2 geomeans. CCP from uninfected vaccinees receiving a third vaccine dose registered a geomean of the GMT<sub>50</sub> of 2,588 (or 10-fold higher nAb geomean of the GMT<sub>50</sub>) to pre-alpha CCP viral assays. In this group the nAb geomean of the GMT<sub>50</sub> fold-reduction against BA.1 was 9, but importantly the geomean of the GMT<sub>50</sub> was close to 300, similar to WA-1 inhibition by WA-1 CCP. The approximately 21-fold reduction in geomean of the GMT<sub>50</sub> from wild-type to BA.1 was reversed by the 10-15-fold increase in nAb geomean of the GMT<sub>50</sub> from either boosted (third-dose) vaccination or Vax-CCP.

In addition to the nAb GMT<sub>50</sub> levels showing potency, the percentage of individuals within a study cohort positive for any level of BA.1 neutralization shows the likelihood of a possible donation having anti-BA.1 activity. All studies but one tested a limited number of 20 to 40 individuals. The pre-Alpha CCP showed that most (18 of 27 studies) had fewer than 50% of individuals tested within a study with measurable BA.1 neutralizing activity: only 2 out of 27 studies indicated that 100% of individuals tested showed BA.1 neutralization (Figure 3). Likewise, most of the studies investigating Alpha and Beta CCP showed similar percent with nAb. Delta CCP had 6 of 7 studies with more than 50% BA.1 neutralization. The plasma from studies of the 2-dose mRNA vaccines indicated a more uniform distributive increase in percent of individual patients with measurable Omicron BA.1 nAb's. The stark contrast is pre-Omicron Vax-CCP, where 14 of 17 studies had 100% of individuals tested with anti-BA.1 nAb. The 3-dose vaccinee studies similarly had 12 of 17 studies with 100% measurable nAb.

Five studies directly compared anti-WA-1 to BA.1 nAb titers in nonvaccinated pre-Alpha, Alpha, Beta, and Delta CCP, and vaccinated plasma with the same nAb assay (Figure 4). nAb GMT<sub>50</sub> against WA-1 was higher for Alpha CCP but lower for Beta CCP. nAb geomean of the GMT<sub>50</sub> against BA.1 was actually highest for delta CCP with geomean levels of 6, 6, 10 for pre-Alpha, Alpha and Delta (Figure 4, panel A). In these 5 studies, nAb geomean of the GMT<sub>50</sub> rose from 2-dose vaccinations to Vax-CCP to the 3-dose boosted vaccination. Importantly, for nAb, geomean of the GMT<sub>50</sub> against BA.1 were 14 to 103 to 195, respectively (Figure 4, panel B).

Another set of 9 matched vaccination studies inclusive of plasma collected after 2- and 3-dose schedules, as well as Vax-CCP, depicted a 20-fold rise in the geomean of the GMT<sub>50</sub> of anti-BA.1 nAb from the 2-dose vaccine to post COVID-19 vaccinees, and a 21-fold increase after the third vaccine dose. The pattern was similar for nAb geomean of the GMT<sub>50</sub> against WA-1 (Figure 4, panel C).

The AZD1222, 3-dose mRNA-1273 and Ad26.COV2 vaccines were understudied, with 3 or less independent studies at different time points, reported in Table 10. The GMT<sub>50</sub> nAb to BA.1 after 3-

mRNA-1273 doses ranged 60 to 2000, with a 5-to-15-fold reduction compared with WA-1. GMT<sub>50</sub> of anti-BA.1 nAbs after AZD1222 vaccine was modest (~10 to 20), as with Ad26.COV2 vaccine (~20 to 40). Two studies reported on post-COVID-19/post-mRNA-1273 with nAb GMT<sub>50</sub> against BA.1 of 38 and 272. Studies with 100% of individual patient samples neutralizing BA.1 included 2 3-dose mRNA-1273 studies, one AZD1222 study, and one post-COVID-19/post-mRNA-1273 study.

Few data exist for comparisons among different vaccine boosts. For CoronaVac® (SinoVac), three doses led to 5.1 fold reduction in anti-BA.1 nAb GMT<sub>50</sub> compared to wild-type<sup>18</sup>, while for Sputnik V nAb titer moved from a 12-fold reduction at 6-12 months up to a 7-fold reduction at 2-3 months after a boost with Sputnik Light<sup>19, 20</sup>. These *in vitro* findings have been largely confirmed *in vivo*, where prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination, protects against BA.1 re-infection<sup>21</sup>.

Eleven studies analyzed the efficacy of CCP and Vax-CCP against Omicron sublineages other than BA.1, i.e. BA.2 and BA.4/5 (summarized in Table 2, Figure 5 and supplement Table 10, 11 and 12). Pre-Omicron (mainly Delta) CCP neutralized less than 40% of BA.1, BA.2 and BA.4/5. Unvaccinated individuals in 3 studies only with BA.1 primary infections poorly neutralized WA-1, with about 75% neutralizations of BA.1, BA.2 and BA.4/5. The 3 vaccine doses of BNT162b2 in 8 studies had a 7-, 6- and 16-fold reduction from WA-1 GM(GMT<sub>50</sub>) of 3,247 with percent of neutralizations all over 95%. Individuals from 11 populations with a BA.1 VaxCCP had a 2-, 2- and 8-fold reduction for WA-1 GM(GMT<sub>50</sub>) of 3578, with 99% Omicron neutralizations. Importantly, GM(GMT<sub>50</sub>) of BA.1 Vax-CCP was more than 1.5 times higher than that of pre-alpha CCP for WA-1. Omicron BA.1, BA.2 and BA.4/5 percent neutralization was over 99% for each. In conclusion, BA.1-Vax- CCP was both high-titer and high neutralization percent.

These studies largely confirm that Omicron CCP *per se* is poorly effective against the cognate or other Omicron sublineages<sup>22</sup> (with the lone exception of cross-reactions among lineages sharing L452 mutations<sup>23</sup> and broad-spectrum nAbs elicited by BA.5<sup>24</sup>). By contrast, both the homologous and the heterologous efficacy of Omicron Vax-CCP is universally preserved<sup>15, 25</sup>. Despite evidence that concentrated pooled human IgGs from convalescent and vaccinated donors have 5-fold reduced potency against BA.5 compared to wild-type SARS-CoV-2<sup>26</sup>, such Vax-CCP derivative is devoid of IgA and IgM nAbs. These findings have important implications if a Vax-CCP program is to be re-launched at the time of BA.2 and BA.4/5 waves. In particular, the emerging R346X-harboring BA.4.6, BA.4.7, and BA.5.9 sublineages show 1.5-1.9-fold reduction in GMT<sub>50</sub> by BA.1/2 Vax-CCP and 2.4-2.6 reduction by BA.5 Vax-CCP<sup>27</sup>. Of interest, Vax-CCP after 2 doses remains superior to 4-dose vaccinee plasma in terms of nAb titers, and Vax-CCP with 3 vaccine doses is not consistently superior to Vax-CCP after 2 vaccine doses<sup>28</sup>.

Differences exist among neutralization assay protocols used across studies. These differences are placed in context once fold-reductions and percent neutralizations are used as reporting measures. The relative geometric mean titer with minimum and maximum titer levels is an alternative perspective. The live virus assays can be sorted from the pseudovirus assays along with the minimum and maximum extracted from the graphs or reported in data from the manuscripts. In general, about 80% of the live virus compared to pseudovirus overlap in dilutional titer magnitude with the pseudovirus assays outlier measurement consistently higher in range from a few studies (Figure 6). However, in some cases the minimum reported is not the limit of detection or quantification, but the lowest number in a group of SARS-CoV-2 antibody positive participants. Graphical depiction of the minimum and maximum dilutional titers are shown in Supplementary Figures 1-11.

207

## 208 Discussion

209 Since nAbs are by definition antiviral, CCP with a high nAb GMT<sub>50</sub> is preferable, and there is now strong  
 210 clinical evidence that nAb titers correlate with clinical benefit in randomized clinical trials<sup>6, 7</sup>. Although  
 211 nAb titers correlate with vaccine efficacy<sup>29, 30</sup>, it is important to keep in mind that SARS-CoV-2-binding  
 212 non-neutralizing antibodies in CCP can similarly provide protection via Fc-mediated functions<sup>31, 32</sup>.  
 213 However, such functions are harder to measure and no automated assay exists for use in clinical  
 214 laboratories. Hence, whereas the presence of a high nAb GMT<sub>50</sub> in CCP is evidence for antibody  
 215 effectiveness *in vitro*, the absence of nAb titer does not imply lack of protection *in vivo* where Fc effects  
 216 mediate protection by other mechanisms such as antibody-dependent cell-mediated cytotoxicity,  
 217 complement activation and phagocytosis.

218 The mechanism by which CCP from vaccinated COVID-19 convalescent individuals better neutralizes  
 219 Omicron lineages is probably a combination of higher amounts of nAb and broader antibody specificity.  
 220 Higher amounts of antibody could neutralize antigenically different variants through the law of mass  
 221 action<sup>33</sup>, whereby even lower affinity antibodies elicited to earlier variants would bind to the Omicron  
 222 variant as mass compensates for reduced binding strength to drive the reaction forward. In addition,  
 223 vaccinated COVID-19 convalescent individuals would have experienced SARS-CoV-2 protein in two  
 224 antigenically different forms: as part of intact infective virions generated *in vivo* during an infectious  
 225 process and as antigens in vaccine preparations. As the immune system processes the same antigen in  
 226 different forms, there are numerous opportunities for processing the protein in different ways that can  
 227 diversify the specificity of the immune response and thus increase the likelihood of eliciting antibodies  
 228 that react with variant proteins. Structurally, it has been shown that third dose mRNA vaccination induces  
 229 mostly class 1/2 antibodies encoded by IGHV1-58;IGHJ3-1 and IGHV1-69;IGHJ4-1 germlines, but not the  
 230 IGHV2-5;IGHJ3-1 germline, i.e. broadly cross-reactive Class 3 antibodies seen after infection<sup>34</sup>.

231 Our analysis provides strong evidence that, unlike what has been observed in Syrian hamster models<sup>35</sup>,  
 232 CCP from unvaccinated donors is unlikely (less than 50%) to have any measurable Omicron neutralization.  
 233 Although the nAb GMT<sub>50</sub> threshold for clinical utility remains poorly defined, it is noticeable that low BA.1  
 234 nAb GMT<sub>50</sub> were generally detected in CCP after infection from pre-Omicron VOCs.

235 However, despite the huge heterogeneity of vaccine schedules, CCP from vaccinated and COVID-19  
 236 convalescent individuals (Vax-CCP) consistently harbors high nAb titers against BA.1 and novel  
 237 sublineages if collected up to 6 months since last event (either vaccine dose or infection). These Omicron  
 238 neutralizing levels are comparable in dilutional titers to that of WA-1 CCP neutralizing WA-1, but their  
 239 prevalence is much higher at this time, facilitating recruitment of suitable donors. Pre-Omicron CCP  
 240 boosted with WA-1-type vaccines induces heterologous immunity that effectively neutralizes Omicron in  
 241 the same assays which rule in or out therapeutic anti-Spike monoclonal antibodies. Consequently,  
 242 prescreening of Vax-CCP donors for nAb titers is not necessary, and qualification of Vax-CCP units remains  
 243 advisable only within clinical trials. A more objective way to assess previous infection (convalescence)  
 244 would be by measuring anti-nucleocapsid (N) antibodies, but unfortunately these vanish quickly<sup>36, 37</sup>.  
 245 Previous symptomatic infection and vaccination can be established by collecting past medical history  
 246 (PMH) during the donor selection visit, which is cheaper, faster, and more reliable than measuring rapidly

declining anti-N antibodies. Although there is no formal evidence for this, it is likely that asymptomatic infection (leading to lower nAb levels in pre-Omicron studies) also leads to lower nAb levels after vaccination compared to symptomatic infection, given that disease severity correlates with nAb titer<sup>38, 39</sup>; hence asymptomatically infected donors missed by investigating PMH are also less likely to be useful.

The same reasoning applies to uninfected vaccinees receiving third dose boosts, but several authorities, including the FDA, do not currently allow collection from such donors for CCP therapy on the basis that the convalescent polyclonal and poly-target response is a prerequisite for efficacy and superior to the polyclonal anti-Spike-only response induced by vaccines. This may be a false premise for recipients of inactivated whole-virus vaccines (e.g., BBIBP-CorV or VLA2001): for BBIBP-CorV, where efficacy against Omicron is largely reduced<sup>18, 20, 40</sup>, but the impact of boost doses is still unreported at the time of writing. Table 1 and Table 9 clearly show that 3-doses of BNT162b2 are enough to restore nAb levels against Omicron in the absence of SARS-CoV-2 infection.

Another point to consider is that information on nAb levels after the third vaccine dose has been almost exclusively investigated for only 1 month of follow-up, while studies on convalescents extend to more than 6 months. At present, it seems hence advisable to start from convalescent vaccinees rather than uninfected 3-dose vaccinees. This is also confirmed by immune escape reported *in vivo* after usage of vaccine (non-convalescent) plasma<sup>41</sup> despite very high nAb titres, likely due to restricted antigen specificity. Vaccine schedules with a delayed boost seem to elicit higher and broader nAb levels than the approved, short schedules<sup>42, 43, 44, 45</sup>, but this remain to be confirmed in larger series. The same is true for breakthrough infections from Alpha or Delta VOC in fully BNT162b2 vaccinated subjects<sup>46</sup>, although variation in time from infection due to successive waves is a major confounder.

With the increase of Omicron seroprevalence in time, polyclonal intravenous immunoglobulins collected from regular donors could become a more standardized alternative to CCP, but their efficacy to date (at the peak of the vaccination campaign) is still 16-fold reduced against Omicron compared to wild-type SARS-CoV-2<sup>47</sup>, and such preparations include only IgG and not IgM and IgA, which have powerful SARS-CoV-2 activity<sup>48, 49</sup>. Nevertheless, the FDA recently reported efficacy of hyperimmune serum against BA.1, BA.2, BA.3, BA.2.12.1, and BA.4/5<sup>50</sup>.

CCP collection from vaccinated convalescents (regardless of infecting sublineage, vaccine type and number of doses) is likely to achieve high nAb titer against VOC Omicron, and, on the basis of lessons learnt with CCP usage during the first 2 years of the pandemic. Although in ideal situations one would prefer RCT evidence of efficacy against Omicron before deployment, there is concern that variants are generated so rapidly that by the time such trials commence this variant could be replaced by another. Given the success of CCP in 2 outpatient RCTs in reducing disease progression or hospitalization<sup>6, 7</sup> and the loss of major mAb therapies due to Omicron antigenic changes, the high titers in 2022 omicron CCP collected from vaccinated convalescents provides an immediate option for COVID-19, especially in LMIC. Given the reduced hospitalization rate with Omicron compared to Delta<sup>51</sup>, it is even more relevant to identify patient subsets at risk of progression in order to minimize the number needed to treat to prevent a single hospitalization. Using the same indications for use of mAb therapies while using the same (now unused) in-hospital facilities seems a logical approach.

We declare we have no conflict of interest related to this manuscript.



287

## 288 References

- 289 1. Ahmed SF, Quadeer AA, McKay M. SARS-CoV-2 T cell responses are expected to remain  
290 robust against Omicron. *Viruses* **14**, 79 (2022).
- 291 2. Bernasconi A, *et al.* Report on Omicron Spike mutations on epitopes and  
292 immunological/epidemiological/kinetics effects from literature. Accessed at  
293 [https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-](https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-literature/770)  
294 [immunological-epidemiological-kinetics-effects-from-literature/770](https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-literature/770) on July 23, 2022.)  
295 (2021).
- 296 3. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal  
297 antibody therapies against SARS-CoV-2. *Lancet Infect Dis*, (2022).
- 298 4. Zhou S, *et al.*  $\beta$ -d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is  
299 Also Mutagenic To Mammalian Cells. *The Journal of Infectious Diseases* **224**, 415-419 (2021).
- 300 5. Jayk Bernal A, *et al.* Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.  
301 *N Engl J Med* **386**, 509-520 (2022).
- 302 6. Libster R, *et al.* Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.  
303 *N Engl J Med* **384**, 610-618 (2021).
- 304 7. Sullivan D, *et al.* Early Outpatient Treatment for Covid-19 with Convalescent Plasma. *N Engl J*  
305 *Med*, (2021).
- 306 8. Vickers MA, *et al.* Exponential increase in neutralizing and spike specific antibodies following  
307 vaccination of COVID-19 convalescent plasma donors. *Transfusion* **61**, 2099-2106 (2021).
- 308 9. Schmidt F, *et al.* High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.  
309 *Nature* **600**, 512-516 (2021).
- 310 10. Di Germanio C, *et al.* Vaccination of COVID-19 Convalescent Plasma Donors Increases  
311 Binding and Neutralizing Antibodies Against SARS-CoV-2 Variants. *Transfusion* **62**, 563-569  
312 (2021).
- 313 11. Munro APS, *et al.* Safety and immunogenicity of seven COVID-19 vaccines as a third dose  
314 (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a  
315 blinded, multicentre, randomised, controlled, phase 2 trial. *The Lancet* **398**, 2258-2276  
316 (2021).
- 317 318
- 319 320
- 321 322
- 323 324
- 325 326

- 327
- 328 12. Franchini M, *et al.* Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta
- 329 and Omicron in vaccine breakthrough-infected blood donors. *Transfusion* **62**, 1171-1176
- 330 (2022).
- 331
- 332 13. Jacobsen H, *et al.* Diminished neutralization responses towards SARS-CoV-2 Omicron VoC
- 333 after mRNA or vector-based COVID-19 vaccinations. 2021.2012.2021.21267898 (2021).
- 334
- 335 14. Planas D, *et al.* Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
- 336 *Nature* **602**, 671-675 (2022).
- 337
- 338 15. Bekliz M, *et al.* Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma,
- 339 Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through
- 340 homologous and heterologous variants. 2021.2012.2028.21268491 (2021).
- 341
- 342 16. Rossler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant
- 343 Neutralization in Serum from Vaccinated and Convalescent Persons. *N Engl J Med* **386**, 698-
- 344 700 (2022).
- 345
- 346 17. Muik A, *et al.* Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited
- 347 human sera. *Science* **375**, 678-680 (2022).
- 348
- 349 18. Zhao X, *et al.* Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and
- 350 protein subunit vaccines and the convalescents. 2021.2012.2016.472391 (2021).
- 351
- 352 19. Dolzhikova IV, *et al.* Sputnik Light booster after Sputnik V vaccination induces robust
- 353 neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant.
- 354 2021.2012.2017.21267976 (2021).
- 355
- 356 20. Bowen JE, *et al.* Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive
- 357 panel of human vaccines. 2022.2003.2015.484542 (2022).
- 358
- 359 21. Carazo S, *et al.* Protection against Omicron re-infection conferred by prior heterologous
- 360 SARS-CoV-2 infection, with and without mRNA vaccination. 2022.2004.2029.22274455
- 361 (2022).
- 362
- 363 22. Turelli P, *et al.* Omicron infection induces low-level, narrow-range SARS-CoV-2 neutralizing
- 364 activity. 2022.2005.2002.22274436 (2022).
- 365
- 366 23. Qu P, *et al.* Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. *N*
- 367 *Engl J Med* **386**, 2526-2528 (2022).

- 368
- 369 24. Richardson SI, *et al.* SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing
- 370 antibodies than BA.1. 2022.2007.2014.500039 (2022).
- 371
- 372 25. Zhou R, *et al.* Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits
- 373 broadly cross-reactive immune responses. *Clin Transl Med* **2**, e720 (2022).
- 374
- 375 26. Aggarwal A, *et al.* SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent
- 376 humoral responses and resistance to clinical immunotherapeutics relative to viral variants of
- 377 concern. 2022.2007.2007.22277128 (2022).
- 378
- 379 27. Jian F, *et al.* Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5
- 380 subvariants. 2022.2008.2009.503384 (2022).
- 381
- 382 28. Xie X, Zou J, Kurhade C, Liu M, Ren P, Shi P-Y. Neutralization of SARS-CoV-2 Omicron
- 383 sublineages by 4 doses of mRNA vaccine. 2022.2007.2029.502055 (2022).
- 384
- 385 29. Khoury DS, *et al.* Neutralizing antibody levels are highly predictive of immune protection
- 386 from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211 (2021).
- 387
- 388 30. Feng S, *et al.* Correlates of protection against symptomatic and asymptomatic SARS-CoV-2
- 389 infection. *Nature Medicine* **27**, 2032-2040 (2021).
- 390
- 391 31. Gilbert PB, *et al.* Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy
- 392 clinical trial. *Science*, eab3435 (2021).
- 393
- 394 32. Earle KA, *et al.* Evidence for antibody as a protective correlate for COVID-19 vaccines.
- 395 *Vaccine* **39**, 4423-4428 (2021).
- 396
- 397 33. Tyrrell DA. Neutralization of viruses by homologous immune serum. II. Theoretical study of
- 398 the equilibrium state. *The Journal of experimental medicine* **97**, 863-870 (1953).
- 399
- 400 34. Andreano E, *et al.* COVID-19 mRNA third dose induces a unique hybrid immunity-like
- 401 antibody response. 2022.2005.2009.491201 (2022).
- 402
- 403 35. Ryan KA, *et al.* Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from
- 404 disease caused by the Omicron variant. 2021.2012.2024.474081 (2021).
- 405
- 406 36. Krutikov M, *et al.* Prevalence and duration of detectable SARS-CoV-2 nucleocapsid
- 407 antibodies in staff and residents of long-term care facilities over the first year of the

408 pandemic (VIVALDI study): prospective cohort study in England. *The Lancet Healthy*  
409 *Longevity*, (2021).

410  
411 37. Amjadi MF, *et al.* Anti-membrane and anti-spike antibodies are long-lasting and together  
412 discriminate between past COVID-19 infection and vaccination. 2021.2011.2002.21265750  
413 (2021).

414  
415 38. Klein S, *et al.* Sex, age, and hospitalization drive antibody responses in a COVID-19  
416 convalescent plasma donor population. *J Clin Invest* **130**, 6141-6150 (2020).

417  
418 39. Focosi D, Franchini M. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in  
419 COVID-19 convalescents: Implications for convalescent plasma donor recruitment. *European*  
420 *journal of haematology* **107**, 24-28 (2021).

421  
422 40. Yu X, *et al.* Pseudotyped SARS-CoV-2 Omicron variant exhibits significant escape from  
423 neutralization induced by a third booster dose of vaccination. 2021.2012.2017.21267961  
424 (2021).

425  
426 41. Gachoud D, *et al.* Antibody response and intra-host viral evolution after plasma therapy in  
427 COVID-19 patients pre-exposed or not to B-cell depleting agents. 2022.2004.2024.22274200  
428 (2022).

429  
430 42. Chatterjee D, *et al.* SARS-CoV-2 Omicron Spike recognition by plasma from individuals  
431 receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. *Cell Rep* **38**,  
432 110429 (2022).

433  
434 43. Grunau B, *et al.* Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals.  
435 *JAMA* **327**, 279-281 (2022).

436  
437 44. Tauzin A, *et al.* A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector  
438 functions and boost pre-existing humoral and T cell responses. *medRxiv [Preprint]*,  
439 2021.2003.2018.435972 (2021).

440  
441 45. Skowronski DM, *et al.* Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and  
442 extended dosing intervals: test-negative design studies from British Columbia and Quebec,  
443 Canada. *Clin Infect Dis*, ciac290 (2022).

444  
445 46. Miyamoto S, *et al.* Vaccination-infection interval determines cross-neutralization potency to  
446 SARS-CoV-2 Omicron after breakthrough infection by other variants.  
447 2021.2012.2028.21268481 (2022).

448

- 449 47. Focosi D, Franchini M. Passive immunotherapies for COVID-19: The subtle line between  
450 standard and hyperimmune immunoglobulins is getting invisible. *Reviews in medical*  
451 *virology*, e2341 (2022).
- 452
- 453 48. Klingler J, *et al.* Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. *J Infect*  
454 *Dis* **223**, 957-970 (2020).
- 455
- 456 49. Wang Z, *et al.* Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Sci Transl Med*, (2020).
- 457
- 458 50. Awasthi M, Golding H, Khurana S. SARS-CoV-2 hyperimmune intravenous human  
459 immunoglobulins neutralizes Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.3 and BA.4/BA.5  
460 for treatment of COVID-19. *Clinical Infectious Diseases*, (2022).
- 461
- 462 51. Wolter N, *et al.* Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant  
463 in South Africa. *Lancet* **399**, 437-446 (2022).
- 464
- 465 52. Zeng C, *et al.* Neutralization and Stability of SARS-CoV-2 Omicron Variant. *bioRxiv*, (2021).
- 466
- 467 53. Liu L, *et al.* Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.  
468 *Nature* **602**, 676-681 (2022).
- 469
- 470 54. Schmidt F, *et al.* Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *N Engl J Med*  
471 **386**, 599-601 (2022).
- 472
- 473 55. Arien KK, *et al.* Three doses of BNT162b2 vaccine confer neutralising antibody capacity  
474 against the SARS-CoV-2 Omicron variant. *NPJ Vaccines* **7**, 35 (2022).
- 475
- 476 56. Lusvarghi S, *et al.* SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum,  
477 but evades most convalescent serum and therapeutic antibodies. *Sci Transl Med*, eabn8543  
478 (2022).
- 479
- 480 57. Hoffmann M, *et al.* The Omicron variant is highly resistant against antibody-mediated  
481 neutralization: Implications for control of the COVID-19 pandemic. *Cell* **185**, 447-456 e411  
482 (2022).
- 483
- 484 58. Zou J, *et al.* Neutralization against Omicron SARS-CoV-2 from previous non-Omicron  
485 infection. *Nat Commun* **13**, 852 (2022).
- 486
- 487 59. Zhang L, *et al.* The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.  
488 *Emerg Microbes Infect* **11**, 1-5 (2022).

489  
490 60. Gruell H, *et al.* mRNA booster immunization elicits potent neutralizing serum activity against  
491 the SARS-CoV-2 Omicron variant. *Nat Med* **28**, 477-480 (2022).

492  
493 61. Dejnirattisai W, *et al.* SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from  
494 neutralizing antibody responses. *Cell* **185**, 467-484 e415 (2022).

495  
496 62. Sheward DJ, *et al.* Variable loss of antibody potency against SARS-CoV-2 B.1.1.529  
497 (Omicron). *bioRxiv*, 2021.2012.2019.473354 (2021).

498  
499 63. Tada T, *et al.* Increased resistance of SARS-CoV-2 Omicron variant to neutralization by  
500 vaccine-elicited and therapeutic antibodies. *EBioMedicine* **78**, 103944 (2022).

501  
502 64. Aggarwal A, *et al.* SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance  
503 to clinical immunotherapeutics relative to viral variants of concern. *medRxiv*,  
504 2021.2012.2014.21267772 (2021).

505  
506 65. Zhao X, *et al.* Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant. *N*  
507 *Engl J Med* **386**, 894-896 (2022).

508  
509 66. Bowen JE, *et al.* Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive  
510 panel of human vaccines. *bioRxiv*, (2022).

511  
512 67. Carreno JM, *et al.* Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.  
513 *Nature* **602**, 682-688 (2022).

514  
515 68. Syed AM, *et al.* Omicron mutations enhance infectivity and reduce antibody neutralization of  
516 SARS-CoV-2 virus-like particles. *medRxiv*, (2022).

517  
518 69. Haveri A, *et al.* Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA  
519 vaccination in health care workers and elderly subjects. *Eur J Immunol*, (2022).

520  
521 70. Li M, *et al.* Convalescent plasma with a high level of virus-specific antibody effectively  
522 neutralizes SARS-CoV-2 variants of concern. *Blood Adv*, 2022.2003.2001.22271662 (2022).

523  
524 71. Kurahashi Y, *et al.* Cross-neutralizing activity against Omicron could be obtained in SARS-  
525 CoV-2 convalescent patients who received two doses of mRNA vaccination. *medRxiv*,  
526 2022.2002.2024.22271262 (2022).

527

- 528 72. Lechmere T, *et al.* Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following  
529 Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. *mBio* **13**, e0379821  
530 (2022).
- 531 73. Edara VV, *et al.* mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing  
532 activity against the SARS-CoV-2 omicron variant. *Cell Rep Med* **3**, 100529 (2022).  
533
- 534 74. Cele S, *et al.* Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.  
535 *Nature* **602**, 654-656 (2022).  
536
- 537 75. Wilhelm A, *et al.* Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera  
538 and Monoclonal Antibodies. *medRxiv*, 2021.2012.2007.21267432 (2021).  
539
- 540 76. Doria-Rose NA, *et al.* Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron  
541 Neutralization. *medRxiv*, 2021.2012.2015.21267805 (2021).  
542
- 543 77. Kawaoka Y, *et al.* Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2.  
544 *Res Sq*, (2022).  
545
- 546 78. Dejnirattisai W, *et al.* Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by  
547 post-immunisation serum. *Lancet* **399**, 234-236 (2022).  
548
- 549 79. Wang Q, *et al.* Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and  
550 BA.5. *Nature*, (2022).  
551
- 552 80. Khan K, *et al.* Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection.  
553 *Nat Commun* **13**, 4686 (2022).  
554
- 555 81. Muik A, *et al.* Omicron BA.2 breakthrough infection enhances cross-neutralization of  
556 BA.2.12.1 and BA.4/BA.5. 2022.2008.2002.502461 (2022).  
557
- 558 82. Planas D, *et al.* Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2  
559 vaccinated individuals, with or without Omicron breakthrough infection.  
560 2022.2007.2022.22277885 (2022).  
561
- 562 83. Yu J, *et al.* Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.  
563 2022.2002.2006.22270533 (2022).  
564
- 565 84. Tuekprakhon A, *et al.* Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine  
566 and BA.1 serum. *Cell* **185**, 2422-2433.e2413 (2022).  
567

568

569 85. Hachmann NP, *et al.* Neutralization Escape by the SARS-CoV-2 Omicron Variants BA.2.12.1  
570 and BA.4/BA.5. *N Engl J Med* **387**, 86-88 (2022).

571


572

573




## Figure 1

PRISMA flowchart for the current study.




## Figure 2

Geometric mean neutralizing titers ( $GMT_{50}$ ) against WA-1 versus Omicron BA.1 by study for A) unvaccinated convalescent plasma and B) vaccinated plasma with or without COVID-19. Geomeans for entire study groups with neutralization of WA-1 in filled circles and of Omicron BA.1 in empty circles with geomeans, fold reduction (FR) above data, and number of studies above x-axis. All geomeans are not statistically significant in difference by multiple comparison in Tukey's test.




## Figure 3

Percent of individual plasma samples in each study showing any titer of Omicron BA.1 neutralization. The percent of samples within a study condition which neutralized Omicron BA.1 graphed in increasing percentages with the number of samples tested on the right y axis. A) pre-Alpha CCP neutralization of Omicron BA.1; B) Alpha, Beta and Delta CCP neutralization of Omicron BA.1 C) 2 dose mRNA vaccines neutralization of Omicron BA.1 D) post-COVID-19/post-vaccine (Vax-CCP) and uninfected 3-dose vaccine neutralization of Omicron BA.1.



## Figure 4


Geometric mean neutralizing titers (GMT<sub>50</sub>) of anti-WA.1 or anti-Omicron BA.1 neutralizing antibodies in plasma samples from 5 studies investigating diverse SARS-CoV-2 infecting lineage or vaccination status. 5 studies characterized A) pre-Alpha, Alpha, Beta and Delta CCP for Omicron BA.1 nAb compared to WA-1, and also B) 2 or 3 doses BNT162b plasma, as well as post-COVID-19 plus BNT162b vaccine (Vax-CCP). C) 9 additional studies looked at the same vaccine conditions in the first 5 comparing WA-1 nAb to Omicron BA.1 nAb.




## Figure 5

Geometric mean neutralizing titers (GMT<sub>50</sub>) against WA-1 versus Omicron BA.1, BA.2 or BA.4/5 for A) boosted vaccinated plasma with or without BA.1 COVID-19 and B) unvaccinated preomicron or BA.1 CCP. Geomeans for entire study groups with neutralization of WA-1 in filled circles with Omicron in empty circles with geomeans and fold reduction (FR) above data and number of studies above x-axis. All geomeans are not statistically significant in difference by multiple comparison in Tukey's test. The percent of samples within a study condition which neutralized Omicron graphed in increasing percentages with the number of samples tested on the right y axis. C) uninfected 3-dose vaccine neutralization of Omicron BA.1, BA.2 and BA.4/5.; D) post-COVID-19-BA.1/post-vaccine (Vax-CCP).


A




B



C




D



## Figure 6

GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. Live virus assays are on the left and pseudoviral assays on the right. A) pre-alpha CCP against WA-1, B) post COVID-19/Vax against WA-1, C) 3 dose BNT 162b2 against WA-1, D) post COVID-19 BA.1/Vac against WA-1, E) pre-alpha CCP against omicron BA.1, F) post COVID-19/Vax against Omicron BA.1, G) 3 dose BNT 162b2 against Omicron BA.1, H) post COVID-19 BA.1/Vac against Omicron BA.1, I) post COVID-19 BA.1/Vac against Omicron BA.2, J) post COVID-19 BA.1/Vac against BA.4/5.



## Table 1

Comparison of WA-1 to Omicron BA.1 nAb and percent with any Omicron BA.1 nAb amongst VOC CCP and vaccination status.

plasma type	number of studies	WA-1 nAb GMT <sub>50</sub>	Omicron BA1 nAb GMT <sub>50</sub>	fold reduction in nAb GMT <sub>50</sub> vs. Omicron BA.1	total number individuals in all studies	total Omicron BA.1 neutralizing number	Omicron BA.1 neutralizing percent
pre-Alpha	27	311	15	20	707	315	45
Alpha	6	301	6	50	64	21	33
Beta	5	91	8	11	37	19	51
Delta	7	464	42	11	94	69	73
2 dose BNT162b2 plasma	22	628	27	24	432	202	47
2 dose mRNA-1273 plasma	9	686	20	35	134	81	60
post-COVID-19/full vacc plasma	19	2753	192	14	279	243	87
3 dose BNT162b2 plasma	17	2588	290	9	310	286	92

## Table 2

Efficacy of CCP, vaccinee plasma and Vax-CCP expressed as GMT<sub>50</sub> against Omicron sublineages.

plasma type	number of studies	WA-1 nAb GMT <sub>50</sub>	Omicron BA.1 nAb GMT <sub>50</sub> (Fold reduction from WA-1)	Omicron BA.2 nAb GMT <sub>50</sub> (Fold reduction from WA-1)	Omicron BA.14/5 nAb GMT <sub>50</sub> (Fold reduction from WA-1)	total number individuals in all studies	Omicron BA.1; BA.2; BA.4/5 neutralizing percent
Pre-omicron CCP	3	1338	133 (10 FR)	132 (10 FR)	177 (8 FR)	50	35; 37;40
BA.1 CCP	3	71	366 (0.16 FR)	180 (0.4 FR)	82 (1 FR)	74	66; 80; 76
BA.4/5 CCP	1	904	557 (2 FR)	884 (1 FR)	1047 (1 FR)	13	100; 100; 100
3 dose BNT162b2 plasma	8	3247	494 (7 FR)	511 (6 FR)	189 (16 FR)	159	97; 98; 96
post-COVID-19-BA.1/full vacc plasma	11	3578	1713 (2 FR)	1830 (2 FR)	454 (8 FR)	142	99; 99; 99



## Supplementary table 1

Synopsis of 27 *in vitro* studies investigating the efficacy of pre-Alpha CCP against Omicron

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min-max)	(pre-Alpha CCP) WA-1 GMT <sub>50</sub>	(pre-Alpha CCP) BA.1 GMT <sub>50</sub>	(pre-Alpha CCP) fold drop vs. BA.1	(pre-Alpha CCP) number in study	(pre-Alpha CCP) BA.1 neutralizing number	(pre-Alpha CCP) BA.1 neutralizing percent
Zeng <sup>52</sup>	2	(1-2) mo	1712	14	122	9	1	11
Liu <sup>53</sup>	2	(9-120) days	4344	135	32	10	2	20
Schmidt <sup>54</sup>	2	1.2 mo	2616	68	38	20	19	95
Schmidt <sup>54</sup>	2	12 mo	2037	136	15	20	17	85
Schmidt <sup>54</sup>	2	6 mo	1678	34	49	20	13	65
Arien <sup>55</sup>	1	1 mo	1086	50	22	10	1	10
Lusvarghi <sup>56</sup>	2	30 (14-51) days	715	25	29	16	2	13
Hoffman <sup>57</sup>	2	< 2 mo	614	8	77	17	8	47
Zou <sup>58</sup>	1	1 mo	601	38	16	64	41	64
Planas <sup>14</sup>	2	6 mo	569	28	20	16	6	38
Planas <sup>14</sup>	2	12 mo	580	29	20	23	8	35
Zhang <sup>59</sup>	2	(1-3) mo	556	66	8	28	28	100
Gruel <sup>60</sup>	2	1.5 mo	494	6	82	30	3	10
Gruel <sup>60</sup>	2	12 mo	93	8	12	30	9	30
Dejnirattisai <sup>61</sup>	1	42 med days	475	28	17	32	32	100
Sheward <sup>62</sup>	2	1 mo	350	40	9	34	25	74
Tada <sup>63</sup>	2	(32-57)	233	9	26	10	4	40
Aggerwal <sup>64</sup>	1	1+ mo	215	10	22	20	0	0
Zhao <sup>65</sup>	2	18 (11-51) days	193	11	17	16	1	6
Bowen <sup>66</sup>	2	(28-78) days	162	10	16	28	13	46
Zou <sup>58</sup>	1	6 mo	142	32	4	36	30	83
Carreno <sup>67</sup>	1	58 (23-87) days	67	6	11	15	4	27
Syed <sup>68</sup>	2	<1 mo	80	20	4	8	6	75
Bekliz <sup>15</sup>	1	(3-137) days	37	1	45	34	5	15
Haveri <sup>69</sup>	1	1 mo	32	2	16	13	0	0
Li <sup>70</sup>	1	<1 mo	28	2	14	108	22	22
Kurahashi <sup>71</sup>	1	(1-3) mo	19	2	13	40	15	38
GM (GMT <sub>50</sub> )			1712	15	20			
Total (AVG%)						707	315	(45%)

## Supplementary table 2

Synopsis of 5 *in vitro* studies investigating the efficacy of Alpha CCP against Omicron

reference	Assay type (live virus =1 Pseudovirus=2 )	time mean or media n (min- max)	(Alpha a CCP) WA-1 GMT <sub>50</sub>	(Alpha a CCP) BA.1 GMT <sub>50</sub>	(Alpha CCP) fold reductio n vs. BA.1	(Alpha CCP) numbe r	(Alpha CCP) BA.1 neutralizin g number	(Alpha CCP) BA.1 neutralizin g percent
Lusvarghi <sup>56</sup>	2	30 (14- 51) days	4978	30	166	4	1	25
Dejnirattisai <sup>61</sup>	1	19 med days	1313	39	34	18	18	100
Rossler <sup>16</sup>	1		256	4	63	10	0	0
Haveri <sup>69</sup>	1	1 mo	32	2	16	20	0	0
Bekliz <sup>15</sup>	1	3-137 days	46	1	57	12	2	17
GM (GMT <sub>50</sub> )			301	6	50			
Total (AVG%)						64	21	(33%)

## Supplementary table 3

Synopsis of 5 *in vitro* studies investigating the efficacy of Beta CCP against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2 )	time mean or media n (min- max)	(beta CCP) WA-1 GMT <sub>50</sub>	(beta CCP) BA.1 GMT <sub>50</sub>	(beta CCP) fold reductio n vs. BA.1	(beta CCP) numbe r	(beta CCP) BA.1 neutralizin g number	(beta CCP) BA.1 neutralizin g percent
Lusvarghi <sup>56</sup>	2	30 (14- 51) days	439	191	2	2	2	100
Dejnirattisai <sup>61</sup>	1	61 med days	327	28	12	14	14	100
Rossler <sup>16</sup>	1		128	4	32	8	1	13
Haveri <sup>69</sup>	1	1 mo	16	2	8	5	0	0
Bekliz <sup>15</sup>	1	3-137 days	21	1	23	8	2	25
GM (GMT <sub>50</sub> )			140	8	11			
Total (AVG%)						37	19	(51%)

## Supplementary table 4

Synopsis of 7 *in vitro* studies investigating the efficacy of Delta CCP against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min- max)	(Delta CCP) WA-1 GMT <sub>50</sub>	(Delta CCP) BA.1 GMT <sub>50</sub>	(Delta CCP) fold drop vs. BA.1	(Delta CCP) number	(Delta CCP) BA.1 neutralizing number	(Delta CCP) BA.1 neutralizing percent
Zeng <sup>52</sup>	2	(1-2) mo	11200	3476	3	19	10	53
Lechmere <sup>72</sup>	2	(13-22) days	668	164	4	14	12	86
Lusvarghi <sup>56</sup>	2	30 (14- 51) days	1211	18	66	15	12	80
Aggerwal <sup>64</sup>	1		770	37	21	10	9	90
Rosler <sup>16</sup>	1		192	8	25	7	1	14
Bekliz <sup>15</sup>	1	3-137 days	73	3	24	10	6	60
Dejnirattisai <sup>61</sup>	1	38 med dayas	47	27	2	19	19	100
GM (GMT <sub>50</sub> )			167	10	17			
Total (AVG%)						94	69	(73%)

## Supplementary table 5

Synopsis of 22 *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 BNT162b2 doses against Omicron.

reference	Assay type (live virus =1 Pseudo virus=2)	time mean or median (min-max)	(2 dose BNT162 b2 plasma) WA-1 GMT <sub>50</sub>	(2 dose BNT162 b2 plasma) BA.1 GMT <sub>50</sub>	(2 dose BNT162 b2 plasma) fold reduction vs. BA.1	(2 dose BNT162 b2 plasma) number	(2 dose BNT162b 2 plasma) BA.1 neutralizing number	(2 dose BNT162b 2 plasma) BA.1 neutralizing percent
Schmidt <sup>54</sup>	2	1 mo	7627	92	83	18	15	83
Liu <sup>53</sup>	2	(16-213) days	4669	222	21	13	6	46
Zeng <sup>52</sup>	2	(21-28) days	2769	121	23	48	13	27
Schmidt <sup>54</sup>	2	5 mo	2435	126	19	18	15	83
Dejnirattisai <sup>61</sup>	1	1 mo	1993	19	105	20	20	100
Chatterjee <sup>42</sup>	2	4 mo	1544	935	2	25	25	100
Syed <sup>68</sup>	2	1-1.5 mo	1280	80	16	21	14	67
Tada <sup>63</sup>	2	90 days	859	25	34	9	7	78
Bowen <sup>66</sup>	2	9-20 days	764	28	27	10	9	90
Chatterjee <sup>42</sup>	2	1 mo	641	105	6	19	10	53
Hoffman <sup>57</sup>	2	<3 mo	604	10	60	11	1	9
Lusvarghi <sup>56</sup>	2	30 (28-34) days	562	22	26	39	3	8
Gruehl <sup>60</sup>	2	1 mo	546	8	68	30	10	33
Rossler <sup>16</sup>	1	1 mo	512	24	21	20	9	45
Edara <sup>73</sup>	1	(14-28) days	384	20	19	13	2	15
Muik <sup>17</sup>	1	1 mo	368	6	61	25	8	32
Cele <sup>74</sup>	1	(10-48) days	263	12	22	8	5	83
Bekliz <sup>15</sup>	1	1 mo	338	4	86	16	11	69
Planas <sup>14</sup>	2	161 (138-176) days	329	30	11	16	1	6
Carreno <sup>67</sup>	1	18 (14-21) days	274	11	25	10	7	70
Gruehl <sup>60</sup>	2	5 mo	139	9	15	30	11	37
Wilheim <sup>75</sup>	1	6 mo	6	1	6	15	0	0
GM (GMT <sub>50</sub> )			628	27	24			
Total (AVG%)						432	202	(47%)

## Supplementary table 6

Synopsis of 9 *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 mRNA-1273 doses against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min- max)	(2 dose mRNA- 1273 plasma) WA-1 GMT <sub>50</sub>	(2 dose mRNA- 1273 plasma) BA.1 GMT <sub>50</sub>	(2 dose mRNA- 1273 plasma) fold drop vs. BA.1	(2 dose mRNA- 1273 plasma) number	(2 dose mRNA- 1273 plasma) BA.1 neutralizing number	(2 dose mRNA- 1273 plasma) BA.1 neutralizing percent
Doria-Rose <sup>76</sup>	2	1 mo	3016	62	49	30	22	73
Syed <sup>68</sup>	2	1-1.5 mo	2560	320	8	10	8	80
Doria-Rose <sup>76</sup>	2	1 mo	2269	27	84	30	22	73
Bowen <sup>66</sup>	2	6-15 days	1155	26	44	11	9	82
Tada <sup>63</sup>	2	80 days	999	38	26	8	5	63
Edara <sup>73</sup>	1	1 mo	745	15	50	11	4	36
Carreno <sup>67</sup>	1	26 (14- 36) days	581	14	42	10	10	100
Rosler <sup>16</sup>	1	5 mo	384	8	48	10	1	10
Wilhelm <sup>75</sup>	1	6 mo	10	1	20	14	0	0
GM (GMT <sub>50</sub> )			644	21	31			
Total (AVG%)						134	81	(60%)

## Supplementary table 7

Synopsis of 17 *in vitro* studies investigating the efficacy of plasma from infected and vaccinated (2 BNT162b2 doses) subjects (Vax-CCP) against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min-max)	(post-COVID-19/full vacc plasma) WA-1 GMT <sub>50</sub>	(post-COVID-19/full vacc plasma) BA.1 GMT <sub>50</sub>	(post-COVID-19/full vacc plasma) fold drop vs. BA.1	(post-COVID-19/full vacc plasma) number	(post-COVID-19/full vacc plasma) BA.1 neutralizing number	(post-COVID-19/full vacc plasma) BA.1 neutralizing percent
Schmidt <sup>54</sup>	2	1 mo	388872	8106	48	17	17	100
Planas <sup>14</sup>	2	32 (21-48) days	78162	1475	53	22	22	100
Tada <sup>63</sup>	2	1 mo	14868	921	16	7	7	100
Cele <sup>74</sup>	1	(18-63)	6763	305	22	13	13	100
Kawoaka <sup>77</sup>	1	1 mo	10002	2029	5	13	13	100
Kawoaka <sup>77</sup>	1	3 mo	2251	399	6	13	13	100
Gruel <sup>60</sup>	2	1.5 mo	7997	1599	5	30	30	100
Arien <sup>55</sup>	1		4822	236	20	10	10	100
Carreno <sup>67</sup>	1	26 (15-39) days	2000	146	14	10	10	100
Dejnirattisai <sup>61</sup>	1	1 mo	1899	215	9	17	17	100
Li <sup>70</sup>	1	< 1 mo	1598	80	20	20	20	100
Bekliz <sup>15</sup>	1	1 mo	1190	65	18	6	6	100
Haveri <sup>69</sup>	1	1 mo	1024	32	32	33	33	100
Rosler <sup>16</sup>	1		1024	256	4	5	5	100
Edara <sup>73</sup>	1	6 mo	625	31	20	24	15	63
Kurahashi <sup>71</sup>	1	1 mo	21	2	14	19	7	37
Wilhelm <sup>75</sup>	1	(.07-7.6) mo	100	10	10	20	5	25
GM (GMT <sub>50</sub> )			2753	192	14			
Total (AVG%)						279	243	(87%)

## Supplementary table 8

Synopsis of 17 *in vitro* studies investigating the efficacy of plasma from uninfected subjects vaccinated with 3 BNT162b2 doses against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min-max)	(3 dose BNT162b2 plasma) WA-1 GMT <sub>50</sub>	(3 dose BNT162b2 plasma) BA.1 GMT <sub>50</sub>	(3 dose BNT162b2 plasma) fold drop vs. BA.1	(3 dose BNT162b2 plasma) number	(3 dose BNT162b2 plasma) BA.1 neutralizing number	(3 dose BNT162b2 plasma) BA.1 neutralizing percent
Schmidt <sup>54</sup>	2	1 mo	65617	3871	17	18	18	100
Planas <sup>14</sup>	2	33 (8-61) days	12739	722	18	20	20	100
Zeng <sup>52</sup>	2	(21-28) days	10412	3179	3	23	20	87
Dejnirattisai <sup>61</sup>	1	1 mo	9219	649	14	20	20	100
Gruehl <sup>60</sup>	2	1 mo	6241	1248	5	30	30	100
Lusvarghi <sup>56</sup>	2	43 (7-93) days	5029	718	7	39	39	100
Tada <sup>63</sup>	2	1 mo	4892	360	14	12	12	100
Liu <sup>53</sup>	2	(14-90) days	4673	715	7	15	15	100
Kawoaka <sup>77</sup>	1	1 mo	2866	485	6	10	10	100
Arien <sup>55</sup>	1		2157	165	13	10	10	100
Hoffman <sup>57</sup>	2	<1 mo	2006	305	7	10	9	90
Edara <sup>73</sup>	1	(17-28) days	1247	89	14	35	31	89
Carreno <sup>67</sup>	1	19 (14-28) days	710	94	8	10	10	100
Syed <sup>68</sup>	2	1-1.5 mo	960	160	6	8	8	100
Muik <sup>17</sup>	1	1 mo	673	106	6	28	27	96
Haveri <sup>69</sup>	1	(21-42) days	256	16	16	7	7	100
Wilhelm <sup>75</sup>	1	3 mo	100	10	10	15	0	0
GM (GMT <sub>50</sub> )		time mean or median (min-max)	2588	290	9			
Total (AVG%)						310	286	(92%)



## Supplementary table 9

Synopsis of *in vitro* studies investigating the efficacy of plasma from uninfected subjects vaccinated with 3 doses of mRNA-1273, AZD-1222 or Ad26.COV2 against BA.1. Because of diversity of vaccines the geomeans and sums were not computed.

reference	vaccine type	WA-1 GMT <sub>50</sub>	fold drop vs. BA.1	BA.1 GMT <sub>50</sub>	number	BA.1 neutralizing number	BA.1 neutralizing percent
Careno <sup>67</sup>	COVID19 + mRNA-1273	3000	11	272	10	10	100
Edara <sup>73</sup>	COVID19 + mRNA-1273 6 mo	931	25	38	13	9	69
Careno <sup>67</sup>	3 dose mRNA-1273	1000	17	60	10	10	100
Doria-Rose <sup>76</sup>	3 dose mRNA-1273	8457	4	2002	30	30	100
Doria-Rose <sup>76</sup>	3 dose mRNA-1273	4216	6	650	30	30	100
Edara <sup>73</sup>	3 dose mRNA-1273	1395	15	96	17	16	94
Dejnirattisai <sup>78</sup>	AZD1222	390	19	21	41	41	100
Rosler <sup>16</sup>	AZD1222	250	25	10.0	20	0	0
Planas <sup>14</sup>	AZD1222 5 mo	187	18	10	18	2	10
Syed <sup>58</sup>	Ad26.COV2	28	1	20.0	9	2	22
Schmidt <sup>54</sup>	Ad26.COV2 1 mo	588	24	25	19	2	11
Schmidt <sup>54</sup>	Ad26.COV2 6 mo	982	23	43	19	11	58

## Supplementary table 10

Synopsis of *in vitro* studies investigating the efficacy of plasma from (pre-omicron, BA.1 and BA.4/5 CCP) subjects against Omicron BA.1, BA.2 and BA.4/5.

reference	Assay type (live virus =1 Pseudovirus =2)	time mean or median (min-max)	WA-1 nAb GMT <sub>50</sub>	Omicron BA.1 nAb GMT <sub>50</sub> (Fold reduction from WA-1)	Omicron BA.2 nAb GMT <sub>50</sub> (Fold reduction from WA-1)	Omicron BA.14/5 nAb GMT <sub>50</sub> (Fold reduction from WA-1)	Number in study	BA.1; BA.2; BA.4/5 neutralizing number	BA.1; BA.2; BA.4/5 neutralizing percent
preomicron									
Wang <sup>79</sup>	1	(7-213) days	5185	845 (6 FR)	939 (6 FR)	596 (9 FR)	22	22; 22;22	100;100 ; 100
Awasthi <sup>50</sup>	2	>1 mo	130	13 (10 FR)	12 (11 FR)	13 (13 FR)	10	1; 1; 1	10; 10; 10
Qu <sup>23</sup>	2	3 day post hosp.	3554	214 (17 FR)	205	717 (5 FR)	18	12; 14; 17	67; 78; 94
GM (GMT <sub>50</sub> )			1338	133 (10 FR)	132 (10 FR)	177 (8 FR)			
Total (AVG%)							50	35; 37;40	(70;74; 80)
BA.1									
Khan <sup>80</sup>	1	23 (19-27iqr)	Not done	275	Not done	36	24	24; nd; 18	100;nd; 75
Zou <sup>58</sup>	1	25 (13-62) days	16	445 (0.04 FR)	107 (0.15 FR)	Not done	20	20; 19; nd	100;95; nd
Qu <sup>23</sup>	2	1-8 days post hosp.	317	399 (0.8 FR)	304 (1.04 FR)	189 (2 FR)	30	22; 21; 23	73;70;77
GM (GMT <sub>50</sub> )			71	366 (0.16 FR)	180 (0.4 FR)	82 (1 FR)	74		
Total (AVG%)								66;40;41	89;80;93
BA.4/5									
Richards <sup>24</sup>	2	< 9 days into hosp.	904	557 (2 FR)	884 (1 FR)	1047 (1 FR)	13	13;13;13	100;100 ; 100

## Supplementary table 11

Synopsis of *in vitro* studies investigating the efficacy of plasma from (post-COVID-19-BA.1/full vacc plasma) subjects (Vax-CCP) against Omicron BA.1, BA.2 and BA.4/5.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or media n (min- max)	WA-1 nAb GMT <sub>50</sub>	Omicron BA.1 nAb GMT <sub>50</sub> (Fold reductio n from WA-1)	Omicron BA.2 nAb GMT <sub>50</sub> (Fold reductio n from WA-1)	Omicron BA.14/5 nAb GMT <sub>50</sub> (Fold reductio n from WA-1)	Numbe r in study	BA.1; BA.2; BA.4/5 neutralizin g number	BA.1; BA.2; BA.4/5 neutralizin g percent
Muik <sup>81</sup> (BA.1)	1	43 (25- 55)	780	656 (1 FR)	800 (1 FR)	156 (5 FR)	14	14;14;13	100;100;93
Muik <sup>81</sup> (BA.2)	1	39 (30- 99)	531	347 (2 FR)	545 (1 FR)	209 (3 FR)	13	13;13;13	100;100; 100
Khan <sup>80</sup>	1		2038	507 (4 FR)		158 (13 FR)	15	15;nd;15	100;nd; 100
Wang <sup>79</sup> (BA.1)	1	(14- 135) days	9500	2406 (4 FR)	2052 (5 FR)	473 (20 FR)	13	13;13;13	100;100; 100
Wang <sup>79</sup> (BA.2)	1	(14- 36) days	9527	3054 (3 FR)	3679 (3 FR)	1627 (6 FR)	12	12;12;12	100;100; 100
Planas <sup>82</sup>	1	80 med days	1000 0	7000 (1 FR)	9000 (1 FR)	1000 (10 FR)	11	11;11;11	100;100; 100
Awasthi <sup>50</sup>	2	>1 mo	1120	733 (2 FR)	380 (3 FR)	76 (15 FR)	6	6;6;6	100;100; 100
Yu <sup>83</sup>	2	14 med days	4046	3249 (1 FR)	2448 (2 FR)		8	7;7;nd	88;88;nd
Richardson <sup>24</sup>	2	< 9 days into hosp.	5484	4244 (1 FR)	3779 (1 FR)	1984 (3 FR)	9	9;9;9	100;100; 100
Tuekprakhon <sup>84</sup>	2	45 med days	5861	3563 (2 FR)	2119 (3 FR)	1064 (6 FR)	14	14;14;14	100;100; 100
Hachman <sup>85</sup>	2	29 (2- 113) days	1105 0	1740 (6 FR)	1910 (6 FR)	590 (19 FR)	27	27;27;27	100;100; 100
GM (GMT <sub>50</sub> )			3578	1713 (2 FR)	1830 (2 FR)	454 (8 FR)			
Total (AVG%)							142	141; 126; 133	99;99;99


## Supplementary table 12

Synopsis of *in vitro* studies investigating the efficacy of plasma from (3 dose BNT162b2 plasma) subjects against Omicron BA.1, BA.2 and BA.4/5.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or media n (min- max)	WA-1 nAb GMT <sub>50</sub>	Omicron BA.1 nAb GMT <sub>50</sub> (Fold reductio n from WA-1)	Omicron BA.2 nAb GMT <sub>50</sub> (Fold reductio n from WA-1)	Omicron BA.14/5 nAb GMT <sub>50</sub> (Fold reductio n from WA-1)	Numbe r in study	BA.1; BA.2; BA.4/5 neutralizin g number	BA.1; BA.2; BA.4/5 neutralizin g percent
Planas <sup>82</sup>	1	132 med days	2000	140 (14 FR)	100 (20 FR)	50 (40 FR)	22	19;20;19	86;91;86
Muik <sup>81</sup>	1	28 (26- 30)	549	90 (6 FR)	93 (6 FR)	37 (15 FR)	18	17;18; 17	94;100;94
Khan <sup>80</sup>	1		4123	208 (20 FR)	Not done	211 (20 FR)	18	18;nd;;18	100;nd; 100
Wang <sup>79</sup>	1	(14- 90) days	6657	130 (5 FR)0	1461 (5 FR)	347 (19 FR)	16	16;16;14	100;100; 88
Qu <sup>23</sup>	2	(21- 28) days	2633	976 (3 FR)	933 (3 FR)	647 (4 FR)	15	14;14;15	93;93; 100
Tuekprakhon <sup>84</sup>	2	28 days	4122	1116 (4 FR)	1113 (4 FR)	360 (11 FR)	19	19;19;19	100;100; 100
Hachman <sup>85</sup>	2	14 days	5783	900 (6 FR)	829 (7 FR)	275 (21 FR)	27	27;27;27	100;100; 100
Yu <sup>83</sup>	2	14 days	6539	1066 (6 FR)	776 (8 FR)	Not done	24	24;24	100;100; nd
GM (GMT <sub>50</sub> )			3247	494 (7 FR)	511 (6 FR)	189 (16 FR)	1		
Total (AVG%)							159	154;138;12 9	97;98;96


## Supplementary Figure 1

Alternative graphing of Supplementary table 1 and Figure 2A. 27 *in vitro* studies investigating the efficacy of pre-Alpha CCP against Omicron with GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.




## Supplementary Figure 2

Alternative graphing of Supplementary table 2 and Figure 2A. 5 *in vitro* studies investigating the efficacy of Alpha CCP against Omicron with GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.




## Supplementary Figure 3

Alternative graphing of Supplementary table 3 and Figure 2A. 5 *in vitro* studies investigating the efficacy of Beta CCP against Omicron with GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



## Supplementary Figure 4

Alternative graphing of Supplementary table 4 and Figure 2A. 7 *in vitro* studies investigating the efficacy of Delta CCP against Omicron with GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.






728

## 729 Supplementary Figure 5

730 Alternative graphing of Supplementary table 5 and Figure 2B. 22 *in vitro* studies investigating the efficacy  
731 of plasma from uninfected recipients of 2 BNT162b2 doses against Omicron with GMT<sub>50</sub> from each study  
732 with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper  
733 panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum  
734 value for each study to normalize for WA-1 on left and omicron on right. The GMT<sub>50</sub> approximates 10  
735 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



736

737


738

739

## Supplementary Figure 6

740

741 Alternative graphing of Supplementary table 6 and Figure 2B. 9 *in vitro* studies investigating the efficacy  
742 of plasma from uninfected recipients of 2 mRNA-1273 doses against Omicron with GMT<sub>50</sub> from each  
743 study with minimum and maximum dilution titer also shown. The absolute values are graphed in the  
744 upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the  
745 minimum value for each study to normalize for WA-1 on left and omicron on right. The GMT<sub>50</sub>  
746 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays  
747 on the right.




748

749

750

# 751 Supplementary Figure 7


752 Alternative graphing of Supplementary table 7 and Figure 2B. 17 *in vitro* studies investigating the efficacy  
753 of plasma from infected and vaccinated (2 BNT162b2 doses) subjects (VaxCCP) against Omicron with  
754 GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. The absolute values are  
755 graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers  
756 divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The  
757 GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on the left and pseudoviral  
758 assays on the right.



759  
760


## Supplementary Figure 8

Alternative graphing of Supplementary table 8 and Figure 2B. 17 *in vitro* studies investigating the efficacy of plasma from uninfected subjects vaccinated with 3 BNT162b2 doses against Omicron with GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.











## Supplementary Figure 9

Alternative graphing of Supplementary table 10 and Figure 5. 7 *in vitro* studies investigating the efficacy of plasma from (pre-omicron, BA.1 and BA.4/5 CCP) subjects (VaxCCP) against Omicron BA.1, BA.2 and BA.4/5 with GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



## Supplementary Figure 10

Alternative graphing of Supplement table 11 and Figure 5. 9 *in vitro* studies investigating the efficacy of plasma from (post-COVID-19-BA.1/full vacc plasma) subjects (VaxCCP) against Omicron BA.1, BA.2 and BA.4/5 with GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



790

## Supplementary Figure 11

Alternative graphing of Supplementary table 12 and Figure 5. 8 *in vitro* studies investigating the efficacy of plasma from (3 dose BNT162b2 plasma) subjects (VaxCCP) against Omicron BA.1, BA.2 and BA.4/5 with GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.

